Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.
SARS-CoV-2
interferon
nonspecific effects of live vaccines
trained immunity
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
25 05 2021
25 05 2021
Historique:
entrez:
19
5
2021
pubmed:
20
5
2021
medline:
29
5
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic triggered an unparalleled pursuit of vaccines to induce specific adaptive immunity, based on virus-neutralizing antibodies and T cell responses. Although several vaccines have been developed just a year after SARS-CoV-2 emerged in late 2019, global deployment will take months or even years. Meanwhile, the virus continues to take a severe toll on human life and exact substantial economic costs. Innate immunity is fundamental to mammalian host defense capacity to combat infections. Innate immune responses, triggered by a family of pattern recognition receptors, induce interferons and other cytokines and activate both myeloid and lymphoid immune cells to provide protection against a wide range of pathogens. Epidemiological and biological evidence suggests that the live-attenuated vaccines (LAV) targeting tuberculosis, measles, and polio induce protective innate immunity by a newly described form of immunological memory termed "trained immunity." An LAV designed to induce adaptive immunity targeting a particular pathogen may also induce innate immunity that mitigates other infectious diseases, including COVID-19, as well as future pandemic threats. Deployment of existing LAVs early in pandemics could complement the development of specific vaccines, bridging the protection gap until specific vaccines arrive. The broad protection induced by LAVs would not be compromised by potential antigenic drift (immune escape) that can render viruses resistant to specific vaccines. LAVs might offer an essential tool to "bend the pandemic curve," averting the exhaustion of public health resources and preventing needless deaths and may also have therapeutic benefits if used for postexposure prophylaxis of disease.
Identifiants
pubmed: 34006644
pii: 2101718118
doi: 10.1073/pnas.2101718118
pmc: PMC8166166
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Clin Microbiol Infect. 2019 Dec;25(12):1459-1467
pubmed: 31449870
Science. 2014 Sep 26;345(6204):1251086
pubmed: 25258085
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Science. 2016 Apr 22;352(6284):aaf1098
pubmed: 27102489
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Sci Adv. 2019 Feb 27;5(2):eaau6849
pubmed: 30820452
Clin Infect Dis. 2021 May 18;72(10):e596-e603
pubmed: 32949460
BMJ Glob Health. 2020 Mar 5;5(3):e002301
pubmed: 32201627
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21
pubmed: 25349379
Clin Immunol. 2014 Dec;155(2):213-9
pubmed: 25451159
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9
pubmed: 25681373
Cell Host Microbe. 2019 Jan 9;25(1):13-26
pubmed: 30629914
Cell. 2020 May 28;181(5):969-977
pubmed: 32437659
Cytokine. 2008 Sep;43(3):336-41
pubmed: 18694646
Lancet. 2020 May 16;395(10236):1545-1546
pubmed: 32359402
Cell Host Microbe. 2020 Aug 12;28(2):322-334.e5
pubmed: 32544459
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33211672
Immunol Res. 2020 Jun;68(3):161-168
pubmed: 32524333
Emerg Microbes Infect. 2020 Dec;9(1):1418-1428
pubmed: 32529952
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Clin Infect Dis. 2015 Nov 15;61(10):1504-11
pubmed: 26219694
J Exp Med. 1964 Jul 1;120:105-20
pubmed: 14194388
Vet Q. 2020 Dec;40(1):169-182
pubmed: 32393111
Cell Rep. 2020 Nov 17;33(7):108387
pubmed: 33207187
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
Vaccine. 2013 Apr 18;31 Suppl 2:B61-72
pubmed: 23598494
Cell. 2018 Jan 11;172(1-2):135-146.e9
pubmed: 29328908
Biochim Biophys Acta Gen Subj. 2019 Oct;1863(10):1480-1497
pubmed: 31121217
J Benefit Cost Anal. 2019;10(Suppl 1):1-14
pubmed: 33282627
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
BMJ. 2010 Nov 30;341:c6495
pubmed: 21118875
Glob Health Action. 2017;10(1):1329968
pubmed: 28580855
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Cell Metab. 2016 Dec 13;24(6):807-819
pubmed: 27866838
Proc R Soc Med. 1931 Sep;24(11):1481-90
pubmed: 19988326
J Gen Virol. 2020 Aug;101(8):791-797
pubmed: 32430094
Viruses. 2019 Jan 09;11(1):
pubmed: 30634396
Int J Epidemiol. 2017 Apr 1;46(2):695-705
pubmed: 27380797
Front Microbiol. 2018 Jan 31;9:83
pubmed: 29445364
J Exp Med. 1969 May 1;129(5):973-92
pubmed: 4976110
JAMA. 2020 Nov 24;324(20):2095-2096
pubmed: 33074293
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Front Immunol. 2018 Dec 07;9:2872
pubmed: 30581436
Science. 2020 Jun 12;368(6496):1187-1188
pubmed: 32527819
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
BMJ Glob Health. 2019 Nov 14;4(6):e001862
pubmed: 31798997
Nat Rev Immunol. 2020 Jun;20(6):375-388
pubmed: 32132681
Science. 2014 Sep 26;345(6204):1250684
pubmed: 25258083
Immunol Rev. 2010 May;235(1):244-66
pubmed: 20536568
Vaccine. 2016 Dec 20;34(52):6707-6714
pubmed: 27773475
Allergy. 2021 Mar;76(3):910-914
pubmed: 32894782
Cell Host Microbe. 2011 May 19;9(5):355-61
pubmed: 21575907
J Exp Med. 1969 May 1;129(5):1079-107
pubmed: 4976109
Cell. 2018 Jan 11;172(1-2):176-190.e19
pubmed: 29328912
BMJ Glob Health. 2020 Mar 5;5(3):e001873
pubmed: 32201619
Clin Infect Dis. 2017 Oct 1;65(7):1183-1190
pubmed: 29579158
Annu Rev Virol. 2019 Sep 29;6(1):567-584
pubmed: 31283436
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Hum Vaccin Immunother. 2020 Nov 1;16(11):2586-2593
pubmed: 32693678
Lancet Infect Dis. 2020 Oct;20(10):e274-e283
pubmed: 32645296
Lancet. 2021 Jan 30;397(10272):398-408
pubmed: 33516338
Nature. 2020 Nov;587(7834):374-376
pubmed: 33139913
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
Autoimmunity. 2011 Jun;44(4):328-47
pubmed: 21250837
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
JAMA. 2020 Oct 20;324(15):1495-1496
pubmed: 33044484
Clin Exp Allergy. 2010 Jun;40(6):933-41
pubmed: 20184606
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
Virus Res. 2020 Sep;286:198074
pubmed: 32589897
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Vaccine. 2020 Jul 22;38(34):5393-5395
pubmed: 32600910
Clin Infect Dis. 2017 Sep 1;65(5):729-737
pubmed: 28481979
Evol Med Public Health. 2020 Oct 14;2020(1):314-322
pubmed: 33335737
Hum Vaccin Immunother. 2021 Nov 2;17(11):3913-3915
pubmed: 34403297
EBioMedicine. 2016 Aug;10:312-7
pubmed: 27498365
Science. 2020 Oct 9;370(6513):237-241
pubmed: 32792465
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32661006
Nat Rev Immunol. 2002 Jun;2(6):417-26
pubmed: 12093008